Basisstatistiken
| CIK | 1157075 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PharmaCyte Biotech, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission F |
|
| April 2, 2026 |
Exhibit 10.1 PHARMACYTE BIOTECH, INC. 2022 EQUITY INCENTIVE PLAN, AS AMENDED (As approved by the stockholders on March 30, 2026) DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| March 9, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 9, 2026 |
2025 ANNUAL REPORTUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ցց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 or տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40699 |
|
| February 27, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40699 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: October 31, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report o |
|
| December 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2025 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| November 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commiss |
|
| November 18, 2025 |
Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.3 Unaudited Pro Forma Condensed Combined Financial Information Summary of Transaction On September 2, 2025, PharmaCyte Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Q/C Technologies, Inc. (“QC”), pursuant to which it agreed to purchase from QC in a private placement (i) shares of QC’s newly designated Series H convertible pref |
|
| November 18, 2025 |
Exhibit 99.2 Q/C Unaudited Condensed Consolidated Financial Statements As of and for the Six Months Ended June 30, 2025 Index to Q/C Unaudited Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Comprehensive Loss 2 Condensed Consolidated Statements of Changes in Stockholders’ Equity 3 Condensed Consolidated Statements of Cash Fl |
|
| November 18, 2025 |
Exhibit 99.1 Q/C Audited Consolidated Financial Statements As of and for the Years Ended December 31, 2024 and 2023 Index to Q/C Audited Consolidated Financial Statements Report of Independent Registered Public Accounting Firm (PCAOB ID No: 03523) 1 Report of Independent Registered Public Accounting Firm (PCAOB ID No: 00536) 5 Consolidated Balance Sheets 6 Consolidated Statements of Comprehensive |
|
| October 31, 2025 |
Exhibit 10.1 PHARMACYTE BIOTECH, INC. 2022 EQUITY INCENTIVE PLAN, AS AMENDED (As approved by the stockholders on October 30, 2025) DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegate |
|
| October 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| October 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| September 26, 2025 |
X0101 EFFECT 33 LIVE 2025-09-26 16:00:00 S-3 0001157075 PharmaCyte Biotech, Inc. 333-290311 |
|
| September 24, 2025 |
PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, NV 89169 PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, NV 89169 September 24, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: PharmaCyte Biotech, Inc. Registration Statement on Form S-3 Filed September 17, 2025 File No. 333-290311 (the “Registration Statement”) Accelera |
|
| September 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| September 23, 2025 |
September 23, 2025 Carlos Trujillo Chief Financial Officer PharmaCyte Biotech, Inc. |
|
| September 17, 2025 |
As filed with the Securities and Exchange Commission on September 16, 2025 Table of Contents As filed with the Securities and Exchange Commission on September 16, 2025 Registration No. |
|
| September 17, 2025 |
PHARMACYTE BIOTECH, INC. Warrant To Purchase Common Stock Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| September 17, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 PharmaCyte Biotech, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common stock |
|
| September 17, 2025 |
Exhibit 3.1 C'E RTlFI C A n: OF D E SI G NATIO N S OF PREFERENCES AND RIGHTS OF SERIES C CONVERTIBLE PREFERRED S TO C K OF PHARMACYTE BlOT EC H , l NC. a Ne v a d a co rp o rati o n I . Designation and Number of Shares . There shall hereby be created and established a series of prefeITed stock of the Company designated as "Series C Convertible Preferred Stock" (the " Pr e f e rr e d S h a re s" ) |
|
| September 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 PHAR |
|
| September 5, 2025 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 2, 2025, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as |
|
| September 5, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 2, 2025, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A.The Company has authorized a new series of co |
|
| September 5, 2025 |
TNF PHARMACEUTICALS, INC. Warrant To Purchase Common Stock Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| September 5, 2025 |
Exhibit 99.1 PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies LAS VEGAS, September 2, 2025 (BUSIN |
|
| September 5, 2025 |
CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. Exhibit 10.2 CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. I, Joshua Silverman, hereby certify that I am the Executive Chairman of TNF Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferred |
|
| September 4, 2025 |
X0708 D LIVE 0001157075 PharmaCyte Biotech, Inc. 3960 HOWARD HUGHES PARKWAY SUITE 500 LAS VEGAS NV NEVADA 89169 (917) 595.2850 NEVADA None NUVILEX, INC. EFOODSAFETY COM INC Corporation true Joshua N. Silverman 3960 HOWARD HUGHES PARKWAY SUITE 500 LAS VEGAS NV NEVADA 89169 Executive Officer Director Carlos Trujillo 3960 HOWARD HUGHES PARKWAY SUITE 500 LAS VEGAS NV NEVADA 89169 Executive Officer Mic |
|
| August 18, 2025 |
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise, Led by Existing Investors Exhibit 99.1 PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise, Led by Existing Investors LAS VEGAS, August 18, 2025 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financing with existing investors involving the sale of 7,000 shares of its newly designated |
|
| August 18, 2025 |
Exhibit 3.1 FORM OF CERTIFICATE OF DESIGNATIONS OF PREFERENCES AND RIGHTS OF SERIES C CONVERTIBLE PREFERRED STOCK OF PHARMACYTE BIOTECH, INC. a Nevada corporation 1. Designation and Number of Shares. There shall hereby be created and established a series of preferred stock of the Company designated as “Series C Convertible Preferred Stock” (the “Preferred Shares”). The authorized number of Preferr |
|
| August 18, 2025 |
GP Nurmenkari, Inc. Member: FINRA & SIPC 22 Elizabeth Street, Suite 1J Norwalk, CT, 06854 Exhibit 10.3 GP Nurmenkari, Inc. Member: FINRA & SIPC 22 Elizabeth Street, Suite 1J Norwalk, CT, 06854 212-447-5550 August 17, 2025 STRICTLY CONFIDENTIAL Pharmacyte Biotech, Inc. 3960 Howard Hughes Parkway Ste 500 Las Vegas, NV 89169 Attn: Carlos A. Trujillo, CFO Dear Mr. Trujillo: This letter (the “Agreement”) constitutes our understanding with respect to the engagement of GP Nurmenkari, Inc., (“ |
|
| August 18, 2025 |
PHARMACYTE BIOTECH, INC. Form of Warrant To Purchase Common Stock Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2025 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| August 18, 2025 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 17, 2025, is by and among Pharmacyte Biotech, Inc., a Nevada corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company has authorized a new series o |
|
| August 18, 2025 |
FORM OF REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August [●], 2025, is by and among PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated |
|
| August 11, 2025 |
Form of Silverman Executive Compensation Agreement Exhibit 10.43 EXECUTIVE COMPENSATION AGREEMENT This Executive Compensation Agreement (“Agreement”) is entered into as of August 8, 2025, effective as of January 1, 2025 (“Effective Date”), by and between PharmaCyte Biotech, Inc. a Nevada corporation (together with its successors and assigns, “Company”), and Josh Silverman (“Executive”). The Company and Executive are each referred to in this Agreem |
|
| August 11, 2025 |
EXHIBIT 4.10 WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEM |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40699 |
|
| August 11, 2025 |
EXHIBIT 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction of Organization Viridis Biotech, Inc. Nevada, USA PharmaCyte Biotech Australia Pty. Ltd. Australia PharmaCyte Biotech Europe Limited Ireland |
|
| August 11, 2025 |
Form of Second Tranche Warrant EXHIBIT 4.11 WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEM |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40699 (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: April 30, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission F |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| March 10, 2025 |
2024 ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 26, 2025 |
Exhibit 16.1 February 26, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by PharmaCyte Biotech, Inc. under Item 4.01 of its Form 8-K dated February 26, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of PharmaCyte Biotech, Inc |
|
| February 26, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| December 4, 2024 |
As filed with the Securities and Exchange Commission on December 4, 2024 As filed with the Securities and Exchange Commission on December 4, 2024 Registration No. |
|
| December 4, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PharmaCyte Biotech, Inc. |
|
| November 13, 2024 |
SC 13G/A 1 ea022071809-13ga4intraphar.htm AMENDMENT NO. 4 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 717512X203 (CUSIP Number) September 30, 2024 (Date of Event Which |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40699 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: July 31, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on F |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 PHAR |
|
| August 13, 2024 |
PharmaCyte Biotech, Inc. Clawback Policy. EXHIBIT 97.1 PHARMACYTE BIOTECH, INC. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of PharmaCyte Biotech, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has the |
|
| August 13, 2024 |
EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 PharmaCyte Biotech, Inc. (“we,” “us,” “our” or the “Company,”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, $0.0001 par value per share (“Common Stock”). The following summary of the material ter |
|
| August 13, 2024 |
PharmaCyte Biotech, Inc. Insider Trading Policy. EXHIBIT 19.1 AMENDED AND RESTATED INSIDER TRADING POLICY This Amended and Restated Insider Trading Policy (“Policy”) was adopted by the Board of Directors (“Board”) of PharmaCyte Biotech, Inc. (together with its subsidiaries, the “Company”) on August 12, 2024 and remains in effect until you are notified in writing of changes to the Policy. This Policy codifies the Company’s standards on trading an |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40699 |
|
| August 13, 2024 |
EXHIBIT 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction of Organization Viridis Biotech, Inc. Nevada, USA PharmaCyte Biotech Australia Pty. Ltd. Australia PharmaCyte Biotech Europe Limited Ireland |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40699 (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: April 30, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on |
|
| May 30, 2024 |
MYMD / MyMD Pharmaceuticals, Inc. / PharmaCyte Biotech, Inc. - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. )* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 62856X102 (CUSIP Number) Carlos Trujillo c/o PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, Nevada 89169 (917) 595-2850 (Name, |
|
| May 23, 2024 |
Form of Long-Term Warrant of MyMD Pharmaceuticals, Inc. Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| May 23, 2024 |
Exhibit 99.1 May 21, 2024 PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value LAS VEGAS-(BUSINESS WIRE)- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the |
|
| May 23, 2024 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of May |
|
| May 23, 2024 |
Form of Short-Term Warrant of MyMD Pharmaceuticals, Inc. Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| May 23, 2024 |
Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (the “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer is executing and deli |
|
| May 23, 2024 |
Exhibit 10.2 CERTIFICATE OF DESIGNATIONS OF SERIES G CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferr |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 1, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission F |
|
| March 27, 2024 |
2023 ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 27, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| February 14, 2024 |
PMCB / PharmaCyte Biotech, Inc. / Ayrton Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2024 |
SC 13G/A 1 ea192875-13ga3intrapharma.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 717512X203 (CUSIP Number) December 31, 2023 (Date of Event Which R |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| November 22, 2023 |
FEMY / Femasys Inc / PharmaCyte Biotech, Inc. - FORM SC-13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 FEMASYS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 31447E 105 (CUSIP Number) Kathy Lee-Sepsick c/o Femasys Inc. 3950 Johns Creek Court, Suite 100 Suwanee, GA (770) 500-3910 (Name, Address and Telephone Number of Person Authorized to Re |
|
| November 16, 2023 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 14, 2023, is by and among Femasys Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of November 14, |
|
| November 16, 2023 |
Exhibit 99.1 New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value LAS VEGAS-(BUSINESS WIRE)- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for w |
|
| November 16, 2023 |
Exhibit 4.1 [FORM OF SERIES A WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE R |
|
| November 16, 2023 |
Exhibit 10.4 COLLABORATION AGREEMENT This Collaboration Agreement (“Agreement”) is effective as of the date of last signature below (“Effective Date”) and is by and between PharmaCyte Biotech, Inc., a Nevada corporation with its principal place of business at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169, United States (“PharmaCyte”), and Femasys Inc., a Delaware corporation, having i |
|
| November 16, 2023 |
Form of Convertible Note of Femasys, Inc. Exhibit 10.2 FORM OF SENIOR UNSECURED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A |
|
| November 16, 2023 |
Exhibit 4.2 [FORM OF SERIES B WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE R |
|
| November 16, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as November 14, 2023, is by and among Femasys Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer is executing and delivering this |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2023 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2023 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| September 27, 2023 |
PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, NV 89169 PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, NV 89169 September 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama and Joe McCann Re: PharmaCyte Biotech, Inc. Registration Statement on Form S-3 Filed September 12, 2023 File No. 333-272569 (the “Registration St |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 PHAR |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40699 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: July 31, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on F |
|
| September 12, 2023 |
As filed with the Securities and Exchange Commission on September 11, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 11, 2023 Registration No. |
|
| September 12, 2023 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) PharmaCyte Biotech, Inc. |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| September 7, 2023 |
Certificate of Change to Articles of Incorporation of the Company, dated September 6, 2023 Exhibit 3.1 Business Entity - Filing Acknowledgement 09/06/2023 Work Order Item Number: Filing Number: Filing Type: Filing Date/Time: Filing Page(s): W2023090600351 - 3131487 20233460427 Certificate Pursuant to NRS 78.209 9/6/2023 8:52:00 AM 1 Indexed Entity Information: Entity ID: C22368 - 1996 Entity Name: PHARMACYTE BIOTECH, INC. Expiration Date: None Entity Status: Active Commercial Registered |
|
| August 4, 2023 |
August 4, 2023 FILED VIA EDGAR Ms. Doris Stacey Gama Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: PharmaCyte Biotech, Inc. Registration Statement on Form S-3 Filed June 9, 2023 File No. 333-272569 Dear Ms. Gama: On behalf of our client, PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), we are |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| August 4, 2023 |
Letter of Armanino LLP to the Securities and Exchange Commission dated August 4, 2023. Exhibit 16.1 Armanino LLP 18101 Von Karman Avenue 14th Floor Irvine, CA 92612-0173 949 224 3300 main 949 224 3399 fax armanino.com August 4, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of the Current Report on Form 8-K of PharmaCyte Biotech, Inc. dated August 4, 2023, which we understand will be filed with the Securities a |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission F |
|
| August 4, 2023 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) PharmaCyte Biotech, Inc. |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40699 |
|
| July 31, 2023 |
EXHIBIT 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction of Organization Viridis Biotech, Inc. Nevada, USA PharmaCyte Biotech Australia Pty. Ltd. Australia PharmaCyte Biotech Europe Limited Ireland |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 19, 2023 |
Amendment No. Six to Bylaws of PharmaCyte Biotech, Inc. Exhibit 3.1 AMENDMENT NO. 6 TO THE BYLAWS OF PHARMACYTE BIOTECH, INC. July 14, 2023 Pursuant to Article 8 of the Amended and Restated Bylaws (“Bylaws”) of PharmaCyte Biotech, Inc., a corporation organized and existing under the laws of the State of Nevada (“Corporation”), the Corporation hereby certifies that: ONE: The Bylaws are hereby amended by this Amendment as follows: Article 4, Section 9 is |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 26, 2023 |
United States securities and exchange commission logo June 26, 2023 Joshua Silverman Interim Chief Executive Officer and Interim President PharmaCyte Biotech, Inc. |
|
| June 16, 2023 |
PMCB / PharmaCyte Biotech Inc / Iroquois Capital Management, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 717512X203 (CUSIP Number) RICHARD AB |
|
| June 15, 2023 |
Press Release, dated June 15, 2023. Exhibit a(6) PharmaCyte Biotech Announces Final Results of Tender Offer LAS VEGAS, June 15, 2023 – (Business Wire) – PharmaCyte Biotech, Inc. |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 PharmaCyte Biotech, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.0001 par value (Title of Class of Securities) 71715X203 (CUSIP Number of Class of Securities) J |
|
| June 9, 2023 |
As filed with the Securities and Exchange Commission on June 9, 2023 As filed with the Securities and Exchange Commission on June 9, 2023 Registration No. |
|
| June 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) PharmaCyte Biotech, Inc. |
|
| June 5, 2023 |
June 5, 2023 FILED VIA EDGAR Mr. Michael Killoy Division of Corporation Finance Office of Mergers & Acquisitions Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: PharmaCyte Biotech, Inc. Schedule TO-I Filed May 11, 2023 File No. 005-91495 Dear Mr. Killoy: On behalf of our client, PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), we are submitting this |
|
| June 5, 2023 |
DEF 14A 1 pharmacytedef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| May 30, 2023 |
May 30, 2023 FILED VIA EDGAR Mr. Michael Killoy Division of Corporation Finance Office of Mergers & Acquisitions Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: PharmaCyte Biotech, Inc. Schedule TO-I Filed May 11, 2023 File No. 005-91495 Dear Mr. Killoy: On behalf of our client, PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), we are submitting this |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 19, 2023 |
PMCB / PharmaCyte Biotech Inc / Ayrton Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 19, 2023 |
United States securities and exchange commission logo May 19, 2023 Joshua Silverman Interim Chief Executive Officer PharmaCyte Biotech, Inc. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 717512X203 (CUSIP Number) RICHARD AB |
|
| May 11, 2023 |
Engagement Letter, dated May 9, 2023, by and between the Company and Katalyst Securities LLC. Exhibit 10.3 KATALYST SECURITIES LLC 655 THIRD AVENUE, 18TH FLOOR NEW YORK, NY 10017 TEL: 212-400-6993 FAX: 212-247-1059 Member: FINRA & SIPC May 9, 2023 STRICTLY CONFIDENTIAL Pharmacyte Biotech, Inc. 3960 Howard Hughes Parkway Ste 500 Las Vegas, NV 89169 Attn: Carlos A. Trujillo, CFO Dear Mr. Trujillo: This letter (the “Agreement”) constitutes our understanding with respect to the engagement of K |
|
| May 11, 2023 |
EXHIBIT (a)(1)(E) Offer to Purchase for Cash by PharmaCyte Biotech, Inc. Up to 7,750,000 Shares of its Common Stock At a Cash Purchase Price of $3.25 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON JUNE 9, 2023, UNLESS THE OFFER IS EXTENDED OR TERMINATED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATION |
|
| May 11, 2023 |
Offer to Purchase, dated May 11, 2023. EXHIBIT (a)(1)(A) Offer to Purchase by PharmaCyte Biotech, Inc. Up to 7,750,000 Shares of its Common Stock At a Cash Purchase Price of $3.25 per Share CUSIP: 71715X203 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON JUNE 9, 2023, UNLESS THE OFFER IS EXTENDED OR TERMINATED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRAT |
|
| May 11, 2023 |
Exhibit 99.1 PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share LAS VEGAS, May 11, 2023 – (Business Wire) – PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.2 |
|
| May 11, 2023 |
Securities Purchase Agreement, dated May 9, 2023. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 9, 2023, is by and among PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer is executing and deliverin |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) PharmaCyte Biotech, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.0001 par value (Title of Class of Securities) 71715X203 (CUSIP Number of Class of Securities) Jos |
|
| May 11, 2023 |
EXHIBIT (a)(1)(F) Notice of Withdrawal For Tender of Shares of Common Stock Pursuant to the Offer to Purchase, Dated May 11, 2023 by PharmaCyte Biotech, Inc. |
|
| May 11, 2023 |
Certificate of Designations of Preferences and Rights of Series B Convertible Preferred Stock Exhibit 3.1 Exhibit A CERTIFICATE OF DESIGNATIONS OF PREFERENCES AND RIGHTS OF SERIES B CONVERTIBLE PREFERRED STOCK OF PHARMACYTE BIOTECH, INC. a Nevada corporation 1. Designation and Number of Shares. There shall hereby be created and established a series of preferred stock of the Company designated as “Series B Convertible Preferred Stock” (the “Preferred Shares”). The authorized number of Prefe |
|
| May 11, 2023 |
Exhibit 4.1 WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEME |
|
| May 11, 2023 |
Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees, dated May 11, 2023. EXHIBIT (a)(1)(D) Offer to Purchase for Cash by PharmaCyte Biotech, Inc. Up to 7,750,000 Shares of its Common Stock At a Cash Purchase Price of $3.25 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON JUNE 9, 2023, UNLESS THE OFFER IS EXTENDED OR TERMINATED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATION |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2023 |
Notice of Guaranteed Delivery. EXHIBIT (a)(1)(C) Notice of Guaranteed Delivery For Tender of Shares of Common Stock of PharmaCyte Biotech, Inc. |
|
| May 11, 2023 |
Letter of Transmittal (including IRS Form W-9). EXHIBIT (a)(1)(B) LETTER OF TRANSMITTAL For Tender of Shares of Common Stock Pursuant to the Offer to Purchase, Dated May 11, 2023 by PharmaCyte Biotech, Inc. |
|
| May 11, 2023 |
Registration Rights Agreement, dated May 9, 2023. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 9, 2023, is by and among PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of May 9, 20 |
|
| May 11, 2023 |
Exhibit 107 Calculation of Filing Fee Table SC TO-I (Form Type) PharmaCyte Biotech, Inc. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| March 16, 2023 |
Certificate of Change to Articles of Incorporation of the Company, dated March 7, 2023. EXHIBIT 3.2 |
|
| February 14, 2023 |
PMCB / PharmaCyte Biotech, Inc. / Shay Capital LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 717512X203 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 2, 2023 |
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan Exhibit 99.1 PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan LAS VEGAS, February 2, 2023 – (Business Wire) – PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-BoxÒ for potential development of cellular therapies for cancer, diabetes and malignant |
|
| February 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2023 |
PMCB / PharmaCyte Biotech, Inc. / SABBY MANAGEMENT, LLC - SABBY 13GA PMCB 1.10.23 Passive Investment SC 13G/A 1 pmcb0123.txt SABBY 13GA PMCB 1.10.23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 717512X203 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| November 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| November 18, 2022 |
Amendment No. Five to Bylaws of PharmaCyte Biotech, Inc. Exhibit 3.1 AMENDMENT NO. 5 TO THE BYLAWS OF PHARMACYTE BIOTECH, INC. November 14, 2022 Pursuant to Article 8 of the Amended and Restated Bylaws (“Bylaws”) of PharmaCyte Biotech, Inc., a corporation organized and existing under the laws of the State of Nevada (“Corporation”), the Corporation hereby certifies that: ONE: The Bylaws are hereby amended by this Amendment as follows: Article 4, Section |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| November 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| October 20, 2022 |
PMCB / PharmaCyte Biotech, Inc. / Shay Capital LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| October 14, 2022 |
Exhibit 10.1 RELEASE AGREEMENT This Release Agreement (?Release?) is entered into by and between PharmaCyte Biotech, Inc. (?Company?) and Gerald W. Crabtree (?Executive?). RECITALS This Release is made with respect to the following facts: WHEREAS, Company and Executive are parties to that certain Executive Compensation Agreement, dated March 10, 2015 (?Executive Agreement?) and subsequent amendmen |
|
| October 7, 2022 |
Exhibit 10.1 SEPARATION, CONSULTING AND RELEASE AGREEMENT This Separation, Consulting and Release Agreement (this ?Agreement?), delivered October 4, 2022, confirms the following understandings and agreements between PharmaCyte Biotech, Inc. (?Company?) and Kenneth L. Waggoner (?you? or ?your?). In consideration of the promises set forth herein, you and the Company agree as follows: 1. Opportunity |
|
| October 7, 2022 |
Exhibit 99.1 PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value Topics to Include Continued Analysis of FDA?s Clinical Hold on IND for Cell-in-a-Box? Las Vegas, Nev., October 7, 2022 ? (Business Wire) ? PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (?PharmaCyte? or the ?Company?), a biotechnology company focused on evaluating |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 PHAR |
|
| August 16, 2022 |
Exhibit 10.2 VIA EMAIL ONLY August 12, 2022 Re: Director Offer Letter Dear , This Director Offer Letter constitutes an agreement (?Agreement?) between you and PharmaCyte Biotech, Inc. (?Company?) and contains all of the terms and conditions relating to your service to the Company as a member of our Board of Directors (?Board?). 1. Term. This Agreement will become effective on the day of execution |
|
| August 16, 2022 |
Exhibit 99.1 PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board LAS VEGAS, NV, August 15, 2022 - (BUSINESS WIRE) - PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| August 16, 2022 |
Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (?Agreement?) is made and entered into as of August 15, 2022, by and among PharmaCyte Biotech, Inc. (?Company?), on the one hand, and Iroquois Master Fund Ltd. and its affiliates (collectively, ?Iroquois Parties?), on the other hand (each of the Company and the Iroquois Parties, a ?Party? and collectively, the ?Parties?). RECITALS WHERE |
|
| August 16, 2022 |
Press Release dated August 15, 2022 Exhibit 99.1 PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board LAS VEGAS, NV, August 15, 2022 - (BUSINESS WIRE) - PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| August 16, 2022 |
Exhibit 10.2 VIA EMAIL ONLY August 12, 2022 Re: Director Offer Letter Dear , This Director Offer Letter constitutes an agreement (?Agreement?) between you and PharmaCyte Biotech, Inc. (?Company?) and contains all of the terms and conditions relating to your service to the Company as a member of our Board of Directors (?Board?). 1. Term. This Agreement will become effective on the day of execution |
|
| August 16, 2022 |
Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (?Agreement?) is made and entered into as of August 15, 2022, by and among PharmaCyte Biotech, Inc. (?Company?), on the one hand, and Iroquois Master Fund Ltd. and its affiliates (collectively, ?Iroquois Parties?), on the other hand (each of the Company and the Iroquois Parties, a ?Party? and collectively, the ?Parties?). RECITALS WHERE |
|
| August 15, 2022 |
Exhibit 99.3 Execution Version COOPERATION AGREEMENT This Cooperation Agreement (?Agreement?) is made and entered into as of August 15, 2022, by and among PharmaCyte Biotech, Inc. (?Company?), on the one hand, and Iroquois Master Fund Ltd. and its affiliates (collectively, ?Iroquois Parties?), on the other hand (each of the Company and the Iroquois Parties, a ?Party? and collectively, the ?Parties |
|
| August 15, 2022 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of PharmaCyte Biotech, Inc., a Nevada corporation. This |
|
| August 15, 2022 |
TERMINATION AGREEMENT August 15, 2022 Exhibit 99.1 TERMINATION AGREEMENT August 15, 2022 Each of the undersigned is a party to that certain Amended and Restated Joint Filing and Solicitation Agreement, dated as of July 11, 2022 (the ?Joint Filing and Solicitation Agreement?). In accordance with Section 10 of the Joint Filing and Solicitation Agreement, each of the undersigned hereby agrees that the Joint Filing and Solicitation Agreem |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 717512X203 (CUSIP Number) RICHARD AB |
|
| July 28, 2022 |
Press Release, dated July 28, 2022, of PharmaCyte Biotech, Inc. PharmaCyte Biotech Rebukes Iroquois? Commencement of Consent Solicitation ? 7% owner Attempting to Take Control of Company Without Paying a Control Premium to Shareholders ? Circumvents Proper Vetting of Directors; Proposes Slate with Multiple Connections and Allegiances to Iroquois with History of Value Destruction ? Proposes 15-Person Board Which is Operationally Inefficient, Violates the Bylaws, and Would Unnecessarily Waste Company Resources ? Attempts to Amend Bylaws to Entrench Itself and Its Own Nominees At The Expense of All Shareholders ? Iroquois? Consent Solicitation Is Full of Factual Inaccuracies and Misrepresentations LAS VEGAS, NV, July 28, 2022, PharmaCyte Biotech, Inc. |
|
| July 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 28, 2022 |
EXHIBIT 10.41 AMENDED AND RESTATED EXECUTIVE COMPENSATION AGREEMENT This Amended and Restated Executive Compensation Agreement (?Agreement?) is entered into as of May 8, 2022, effective as of January 1, 2022 (?Amendment Date?), by and between PharmaCyte Biotech, Inc. a Nevada corporation (together with its successors and assigns, ?Company?), and Carlos A. Trujillo (?Trujillo?). The Company and Tru |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| July 28, 2022 |
PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan. Exhibit 10.42 2021 Plan PHARMACYTE BIOTECH, INC. 2021 EQUITY INCENTIVE PLAN Section 1. Purpose; Definitions. The purposes of the PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan (as amended from time to time, the ?Plan?) are to: (a) enable PharmaCyte Biotech, Inc. (the ?Company?) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provid |
|
| July 28, 2022 |
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation PharmaCyte Biotech Rebukes Iroquois? Commencement of Consent Solicitation ? 7% owner Attempting to Take Control of Company Without Paying a Control Premium to Shareholders ? Circumvents Proper Vetting of Directors; Proposes Slate with Multiple Connections and Allegiances to Iroquois with History of Value Destruction ? Proposes 15-Person Board Which is Operationally Inefficient, Violates the Bylaws, and Would Unnecessarily Waste Company Resources ? Attempts to Amend Bylaws to Entrench Itself and Its Own Nominees At The Expense of All Shareholders ? Iroquois? Consent Solicitation Is Full of Factual Inaccuracies and Misrepresentations LAS VEGAS, NV, July 28, 2022, PharmaCyte Biotech, Inc. |
|
| July 28, 2022 |
EXHIBIT 10.40 AMENDED AND RESTATED EXECUTIVE COMPENSATION AGREEMENT This Amended and Restated Executive Compensation Agreement (?Agreement?) is entered into as of May 8, 2022, effective as of January 1, 2022 (?Amendment Date?), by and between PharmaCyte Biotech, Inc. a Nevada corporation (together with its successors and assigns, ?Company?), and Kenneth L. Waggoner (?Executive?). The Company and t |
|
| July 28, 2022 |
EXHIBIT 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction of Organization Bio Blue Bird AG Lichtenstein Viridis Biotech, Inc. Nevada PharmaCyte Biotech Australia Pty. Ltd. Australia PharmaCyte Biotech Europe Limited Ireland |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 28, 2022 |
EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 PharmaCyte Biotech, Inc. (?PharmaCyte? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (?Exchange Act?): common stock, $0.0001 par value per share (?Common Stock?). The Company?s Common Stock has |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40699 |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| July 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 21, 2022 |
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study Exhibit 99.1 PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study LAS VEGAS, NV, July 21, 2022-(BUSINESS WIRE)- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box?, announced today that it has commenced the pilot phase o |
|
| July 21, 2022 |
Press Release, dated July 21, 2022, of PharmaCyte Biotech, Inc. Exhibit 99.1 PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study LAS VEGAS, NV, July 21, 2022-(BUSINESS WIRE)- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box?, announced today that it has commenced the pilot phase o |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 19, 2022 |
Press Release, dated July 19, 2022, of PharmaCyte Biotech, Inc. Exhibit 99.1 PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study LAS VEGAS, NV, July 19, 2022?(BUSINESS WIRE)?PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box?, announced today that it has a |
|
| July 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 19, 2022 |
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study Exhibit 99.1 PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study LAS VEGAS, NV, July 19, 2022?(BUSINESS WIRE)?PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box?, announced today that it has a |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 717512X203 (CUSIP Number) RICHARD AB |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| July 11, 2022 |
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 Exhibit 99.1 PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 LAS VEGAS, NV, July 11, 2022 (BUSINESS WIRE) - PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box?, today announced its prelimina |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 11, 2022 |
AMENDED AND RESTATED JOINT FILING AND SOLICITATION AGREEMENT EX-99.2 3 ex992to13da211375004071122.htm AMENDED AND RESTATED JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.2 AMENDED AND RESTATED JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”); WHEREAS, Iroquois Master Fund Ltd., a Cayman Islands exempted limited company, Ir |
|
| July 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 11, 2022 |
Press Release, dated July 11, 2022, of PharmaCyte Biotech, Inc. Exhibit 99.1 PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 LAS VEGAS, NV, July 11, 2022 (BUSINESS WIRE) - PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box?, today announced its prelimina |
|
| July 11, 2022 |
EX-99.3 4 ex993to13da211375004071122.htm POWERS OF ATTORNEY Exhibit 99.3 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Richard Abbe and Kimberly Page, or either of them, the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with |
|
| July 11, 2022 | ||
| July 11, 2022 |
Exhibit 99.1 IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS New York, NY ? July 11, 2022 ? Iroquois Capital Management, LLC (together with its affiliates, ?Iroquois?), announced that on Friday, July 8, 2022, that it had delivered a written consent to PharmaCyte Biotech, Inc. (?PharmaCyte?, ?PMCB? or the ?Company?) (NASDAQ:PMCB) seeking the con |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| June 23, 2022 |
Exhibit 99.3 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Richard Abbe and Kimberly Page, or either of them, the undersigned?s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned?s beneficial ownership of, or participation in a group with respect to, securities of PharmaCyte Biotech, Inc. (the ?Com |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 1)1 PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 717512X203 (CUSIP Number) RICHARD AB |
|
| June 23, 2022 | ||
| June 23, 2022 |
EX-99.1 2 ex991to13da111375004062322.htm PRESS RELEASE Exhibit 99.1 IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE’S 2022 ANNUAL MEETING Believes Truly Independent Board Required to Increase Accountability Given PharmaCyte’s Long History of Missed Milestones Highlights Severe Governance Deficiencies and Recent Half-Baked Efforts to Appease Stock |
|
| June 23, 2022 |
JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.2 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of PharmaCyte Biotech, Inc., a Nevada corporation (the ?Company?); WHEREAS, Iroquois Master Fund Ltd., a Cayman Islands exempted limited company, Iroquois Capital Management, LLC, a Delaware limited liability company, Iroquois Capital Investment Group LLC, a Delaware lim |
|
| June 15, 2022 |
Press Release, dated June 15, 2022, of PharmaCyte Biotech, Inc. Exhibit 99.1 PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital?s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value LAS VEGAS, NV, June 15, 2022, PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation te |
|
| June 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 15, 2022 |
Exhibit 99.1 PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital?s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value LAS VEGAS, NV, June 15, 2022, PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation te |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 7, 2022 |
Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 5, 2022 |
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors EX-99.1 2 pharmacyteex9901.htm PRESS RELEASE Exhibit 99.1 PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors LAS VEGAS, NV, April 5, 2022 (BUSINESS WIRE) - PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the appoi |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission F |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| March 9, 2022 |
Exhibit 99.1 ? This document may include statements by PharmaCyte Biotech that constitute ?forward - looking statements.? Such statements are often characterized by the terms ?may,? ?believes,? expects? or ?anticipates? and do not reflect facts. ? Forward - looking statements involve risks, uncertainties and other factors that may cause actual results, performance or achievements of PharmaCyte and |
|
| March 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 1, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| February 17, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 717512X203 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 P |
|
| November 22, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-260849 PROSPECTUS PHARMACYTE BIOTECH, INC. 8,050,000 SHARES OF COMMON STOCK ISSUED PURSUANT TO THE EXERCISE OF WARRANTS This prospectus relates to the resale by the selling stockholders (?Selling Stockholders?) named herein, including their transferees, pledgees or donees, or their respective successors, of up to 8,050,000 shares (?Shares?) of |
|
| November 15, 2021 |
United States securities and exchange commission logo November 15, 2021 Kenneth L. |
|
| November 15, 2021 |
PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway Suite 500 Las Vegas, NV 89169 PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway Suite 500 Las Vegas, NV 89169 November 15, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Gary Guttenberg Re: PharmaCyte Biotech, Inc. Registration Statement on Form S-3 Filed November 8, 2021 File No. 333-260849 Ladies and Gentlem |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 As filed with the Securities and Exchange Commission on November 5, 2021 Registration No. |
|
| November 4, 2021 |
PMCB / PharmaCyte Biotech, Inc. / Iroquois Capital Management, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. )1 PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 717512X203 (CUSIP Number) RICHARD ABB |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40699 PHAR |
|
| September 10, 2021 |
Exhibit 99.1 ? This document may include statements by PharmaCyte Biotech that constitute ?forward - looking statements.? Such statements are often characterized by the terms ?may,? ?believes,? expects? or ?anticipates? and do not reflect facts. ? Forward - looking statements involve risks, uncertainties and other factors that may cause actual results, performance or achievements of PharmaCyte and |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commissio |
|
| August 30, 2021 |
PMCB / PharmaCyte Biotech, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PharmaCyte Biotech, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 717512X203 (CUSIP Number) August 19, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| August 30, 2021 |
PMCB / PharmaCyte Biotech, Inc. / SABBY MANAGEMENT, LLC - SABBY 13G PMCB 8.30.21 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 23, 2021 |
Form of Series A Warrant Common Stock Purchase Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 23, 2021 |
Securities Purchase Agreement, dated as of August 19, 2021. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 19, 2021, between PharmaCyte Biotech, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| August 23, 2021 |
Form of Placement Agent Common Stock Purchase Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 23, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-255044 and 333-258921 PROSPECTUS SUPPLEMENT (To Prospectus dated April 14, 2021) 8,430,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 5,570,000 Shares of Common Stock We are offering 8,430,000 shares (“Shares”) of our common stock, par value $0.0001 per share and Pre-funded Warrants (“Pre-funded Warrants”) to purchase up to 5 |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission |
|
| August 23, 2021 |
Exhibit 99.1 PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules LAGUNA HILLS, CA, August 19, 2021 (BUSINESS WIRE)?PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box?, tod |
|
| August 23, 2021 |
Form of Pre-Funded Common Stock Purchase Warrant. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PHARMACYTE BIOTECH, INC. Warrant Shares: Issue Date: August 23, 2021 Initial Exercise Date: August 23, 2021 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth |
|
| August 19, 2021 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHARMACYTE BIOTECH, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 62-1772151 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 23046 Avenida de la Carlota Suite 600 La |
|
| August 12, 2021 |
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering Exhibit 99.1 PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering LAGUNA HILLS, CA, August 9, 2021 (BUSINESS WIRE)?PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box?, today announced th |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 PHARMACYTE BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-40699 62-1772151 (State or other jurisdiction of incorporation) (Commission F |
|
| August 12, 2021 |
Exhibit 4.3 UNDERWRITER COMMON STOCK PURCHASE WARRANT PharmaCyte Biotech, Inc. Warrant Shares: Issue Date: August 12, 2021 Initial Exercise Date: August 12, 2021 THIS Underwriter COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for |
|
| August 12, 2021 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PHARMACYTE BIOTECH, INC. Warrant Shares: Issue Date: , 2021 Initial Exercise Date: , 2021 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| August 12, 2021 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT PharmaCyte Biotech, Inc. Warrant Shares: Issue Date: , 2021 Initial Exercise Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set f |
|
| August 12, 2021 |
Underwriting Agreement, dated as of August 9, 2021 Exhibit 1.1 PharmaCyte Biotech, Inc. 2,630,385 Shares of Common Stock (par value $0.0001 per share) 899,027 Pre-Funded Warrants to Purchase Shares of Common Stock and Warrants to Purchase 3,529,412 Shares of Common Stock Underwriting Agreement August 9, 2021 H.C. Wainwright & Co., LLC As Representative of the several Underwriters listed in Schedule A hereto 430 Park Avenue, 4th Floor New York, NY |
|
| August 10, 2021 | ||
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40699 PHARMACYTE BIOTECH |
|
| August 10, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-255044 PROSPECTUS SUPPLEMENT (To Prospectus dated April 14, 2021) 2,630,385 Shares of Common Stock Pre-funded Warrants to Purchase up to 899,027 Shares of Common Stock Common Warrants to Purchase up to 3,529,412 Shares of Common Stock Underwriter Warrants to Purchase 264,706 Shares of Common Stock We are offering 2,630,385 shares of our common |
